Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Terminated NCT05575440

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Conditions: Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Enrollment: 11
Sponsor: Mayo Clinic

Location: Mayo Clinic in Rochester Rochester Minnesota

Summary

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Eligibility Criteria

Inclusion Criteria: * Subject has biopsy-proven papillary or follicular thyroid cancer * Subject is clinically indicated for 123I-SPECT/CT total body iodine (TBI) scan * Subject agrees to undergo 18F-TFB PET/CT scan following TBI scan * Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/World Health Organization \[WHO\] equivalent) * Subject is able to be scanned - able to lie still on SPECT/CT and PET/CT scanner table for up to 65 minutes (min) * Age 18 or older * Ability to understand a written informed consent document, and the willingness to sign it * Subject is not pregnant Exclusion Criteria: * Contrast-enhanced CT within 4 last weeks * Amiodarone within last 4 months * Ingested iodine, kelp tablets, Lugols iodine, or potassium iodide (SSKI) within 2 weeks * Unable to lie flat, still or tolerate a PET scan * Applied betadine, iodoform, or quick tanning products to skin within last two weeks * If using medication withdrawal for stimulation, then exclude if thyroid stimulating hormone (TSH) level \< 25 * Taken anti-thyroid medication within 1 week * Subject is breastfeeding * Positive pregnancy test

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05575440). StuddyBuddy aggregates publicly available trial information.